Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $19.50 Consensus Price Target from Analysts

Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) has received a consensus rating of “Buy” from the six brokerages that are presently covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have updated their coverage on the stock in the […]

Related Keywords

United States ,William Blair ,Maxim Group ,Visionpoint Advisory Group ,Nasdaq ,Zevra Therapeutics Company Profile ,Commonwealth Equity Services ,Kingsview Wealth Management ,Zevra Therapeutics Inc ,International Assets Investment Management ,Cantor Fitzgerald ,Tower Research Capital ,Zevra Therapeutics ,Get Free Report ,Marketbeat Ratings ,Point Advisory Group ,Assets Investment Management ,Equity Services ,Wealth Management ,Research Capital ,Get Free ,Ligand Activated Therapy ,Zevra Therapeutics Daily ,